CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
R-(-)-gossypol acetic acid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00773955
NCT00773955Phase 2Completed
CompareCT.gov

A Phase II Study of AT-101 in Recurrent Extensive Stage Small Cell Lung Cancer

National Cancer Institute (NCI)·interventional·Posted Oct 16, 2008·Updated May 12, 2014

In Brief

A Phase 2 clinical trial evaluating R-(-)-gossypol acetic acid, pharmacological study, and 1 other intervention for Extensive Stage Small Cell Lung Cancer and Recurrent Small Cell Lung Cancer. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2008
Enrollment StartNov 1, 2008
Primary CompletionOct 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.7 years ago

Interventions

R-(-)-gossypol acetic aciddrug

Given orally

pharmacological studyother

Correlative studies

laboratory biomarker analysisother

Correlative studies